Effects of galantamine on attention and memory in Alzheimer's disease measured by computerized neuropsychological tests: results of the Brazilian Multi-Center Galantamine Study (GAL-BRA-01)

Department of Neurology, University of São Paulo, São Paulo, SP, Brazil.
Arquivos de Neuro-Psiquiatria (Impact Factor: 1.01). 07/2004; 62(2B):379-84. DOI: 10.1590/S0004-282X2004000300001
Source: PubMed

ABSTRACT To investigate the effects of galantamine on the performance of patients with mild to moderate Alzheimer's disease (AD) in a computerized neuropsychological test battery (CNTB).
Thirty-three patients with probable AD were treated with galantamine for three months and evaluated in a prospective, open-label, multi-center study. The CNTB and the ADAS-Cog were administered at baseline and after 12 weeks. The CNTB includes reaction time tests to evaluate attention, implicit and episodic memory for faces and words. Statistical comparisons were performed between the results in week 12 versus baseline. Patients who did not reach the therapeutic doses were excluded from the efficacy analysis.
Four patients (12.1%) were excluded from the analysis either because of treatment discontinuation (n=3) or because a therapeutic dose was not reached (n=1). The remaining 29 patients were treated with doses of 24 mg/day (n=22) and 16 mg/day (n=7). After 12 weeks, significant reductions in reaction time were seen in the test of episodic memory for faces (p=0.023) and in the test of two-choice reaction time (p=0.039) of the CNTB.
Treatment with galantamine produced improvement in computerized tests of attention and episodic memory after 12 weeks, leading to statistically significant reduction in the reaction times.

Download full-text


Available from: Francisco de Assis Carvalho do Vale, Aug 15, 2014
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This article reports the case of a high-functioning patient who had an "event" diagnosed as probable transient global amnesia (TGA) 1 year before being diagnosed with evolving cognitive impairment. Formal psychometric testing was necessary to make this diagnosis owing to the insensitivity of simple tests in this high-functioning individual. Neuropsychological evaluation showed impairment of short-term verbal memory, compounded by observed fluctuations in attention. In light of its reported benefits for cognitive function and attention, galantamine was administered starting at 4 mg b.i.d., then increasing to 8 mg b.i.d. and finally to 12 mg b.i.d. During galantamine dose escalation, the patient experienced transient vomiting on the first day of taking 12 mg b.i.d. With reassurance, he returned to the same dose and tolerated it during long-term treatment without problems. His cognitive function has remained at an improved level for 18 months on galantamine administration.
    The Primary Care Companion to The Journal of Clinical Psychiatry 02/2004; 6(6):248-251. DOI:10.4088/PCC.v06n0606
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mild cognitive impairment (MCI) causes memory impairment and executive function deficits in those with the condition. There is also some evidence that MCI patients are impaired in their daily functioning. Cholinesterase inhibitors have been widely used for patients with Alzheimer's disease (AD), with evidence of improving cognitive function. There is currently no established treatment for MCI, and cholinesterase inhibitors are beginning to be studied in these patients. Galantamine is a cholinesterase inhibitor that also has nicotinic receptor-modulating properties that has been successful in improving AD patients. This study examined the effects of galantamine in patients with MCI in areas of memory, executive functioning, and global functioning. There was a significant improvement in scores on the Functional Activities Questionnaire, which is a measure of global functioning. There were also improvements in the galantamine group on two of six measures in the Cambridge Automated Neuropsychiatric Test Assessment Battery and in immediate free recall on the California Verbal Learning Test.
    American Journal of Alzheimer s Disease and Other Dementias 09/2005; 20(5):295-302. DOI:10.1177/153331750502000502 · 1.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this article is to discuss new data on presently approved drugs for dementia, such as cholinesterase inhibitors and memantine, and concerns regarding the use of antipsychotics for treating neuropsychiatric symptoms, as well as to summarize some relevant studies recently published on emerging therapies with potential disease-modifying effects. The main focuses of recent studies of cholinesterase inhibitors and memantine have been on efficacy and safety aspects in extended clinical trials, combined treatments or comparative analysis between agents, and also on potential neuroprotective effects and new indications. Other publications have assessed the evidence of efficacy and the increased risk of cerebrovascular events, rapid cognitive decline, and mortality with the use of antipsychotics in dementia, providing important information in relation to the controversy surrounding its use. Although more studies are warranted, a sizable literature on novel treatment options under investigation is currently available as a result of a better understanding of pathogenesis of dementia. So far, there is no established method to predict better responders or long-term benefits with currently approved drugs for treatment of dementia. Recent systematic reviews and new research on current treatment, however, provide valuable information for clinicians, and novel drugs under investigation reveal promising new therapeutic strategies.
    Current Opinion in Psychiatry 12/2006; 19(6):575-80. DOI:10.1097/01.yco.0000245756.29244.b9 · 3.55 Impact Factor
Show more